Invitrogen Reaches Key Milestone in its Agreement with Blue Heron Biotechnology
News Oct 19, 2007
Invitrogen Corporation has reached a key milestone in its agreement with Blue Heron Biotechnology and is now the co-exclusive worldwide distributor with Blue Heron for its custom gene synthesis services.
Blue Heron Biotechnology says that its proprietary GeneMaker® platform can synthesize gene sequences with perfect accuracy which makes it ideal for researchers studying anything from single genes up to entire genomes as in the biofuels and synthetic biology markets.
Researchers worldwide are increasingly turning to synthetic genes as a convenient, cost-effective alternative for traditional cloning. Synthetic genes have allowed pharmaceutical and biotechnology companies to speed the drug discovery process by rapidly and accurately synthesizing genes of interest that are in turn used to produce novel proteins, new vaccines and diagnostics.
"For decades, researchers have depended on Invitrogen's cloning platforms and gene collections to advance their gene discovery and functional genomics experiments. With new technologies that allow the economical production of synthetic genes, researchers can expand the possibilities of science," said Dr. Balwant Patel, general manager for Cloning and Protein Expression at Invitrogen.
"Our relationship with Blue Heron means that our customers will explore those possibilities with the best synthetic genetics technologies and the most highly regarded cloning and expression platforms available commercially," Dr. Patel added.
"This relationship creates unique opportunities to serve the needs of the research community. We are very enthusiastic about bringing Blue Heron's technological leadership in gene synthesis to Invitrogen's unmatched worldwide customer base," said John Fess, CEO of Blue Heron.
Back in 2009, researchers identified a herd of Awassi sheep suffering from "day blindness". As that term implies, these sheep were blind during the day (in bright light) but could see at night, in low-light conditions. After identifying the genetic basis of this blindness, researchers have now successfully used gene therapy to restore their daytime vision.READ MORE